Tumor Immunity Therapy Market, Global Outlook and Forecast 2022-2028

August 2022 | 105 pages | ID: T08F9E2FCA81EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Tumor Immunity Therapy in Global, including the following market information:

Global Tumor Immunity Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Tumor Immunity Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immune Checkpoint Inhibitor Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor Immunity Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor Immunity Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Tumor Immunity Therapy Market Segment Percentages, by Type, 2021 (%)

• Immune Checkpoint Inhibitor
• Cytokine Immunotherapy
• Cancer Vaccine
• Car-t Cell Therapy
• Others

Global Tumor Immunity Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Tumor Immunity Therapy Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic

Global Tumor Immunity Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Tumor Immunity Therapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Tumor Immunity Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Tumor Immunity Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bristol-Myers Squibb
• Merck & Co., Inc.
• Roche AG
• AstraZeneca, Plc
• Sanofi S.A.
• Dendreon Pharmaceuticals
• Novartis
• Gilead Sciences Inc.
• IMVAQ Therapeutics
• Arch Oncology
• Juno Therapeutics
• Refuge
• Lepu Biopharma
• Genoimmune
• TCR Cure

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Tumor Immunity Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Tumor Immunity Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL TUMOR IMMUNITY THERAPY OVERALL MARKET SIZE

2.1 Global Tumor Immunity Therapy Market Size: 2021 VS 2028
2.2 Global Tumor Immunity Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Tumor Immunity Therapy Players in Global Market
3.2 Top Global Tumor Immunity Therapy Companies Ranked by Revenue
3.3 Global Tumor Immunity Therapy Revenue by Companies
3.4 Top 3 and Top 5 Tumor Immunity Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Tumor Immunity Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunity Therapy Players in Global Market
  3.6.1 List of Global Tier 1 Tumor Immunity Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Tumor Immunity Therapy Market Size Markets, 2021 & 2028
  4.1.2 Immune Checkpoint Inhibitor
  4.1.3 Cytokine Immunotherapy
  4.1.4 Cancer Vaccine
  4.1.5 Car-t Cell Therapy
  4.1.6 Others
4.2 By Type - Global Tumor Immunity Therapy Revenue & Forecasts
  4.2.1 By Type - Global Tumor Immunity Therapy Revenue, 2017-2022
  4.2.2 By Type - Global Tumor Immunity Therapy Revenue, 2023-2028
  4.2.3 By Type - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Tumor Immunity Therapy Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
5.2 By Application - Global Tumor Immunity Therapy Revenue & Forecasts
  5.2.1 By Application - Global Tumor Immunity Therapy Revenue, 2017-2022
  5.2.2 By Application - Global Tumor Immunity Therapy Revenue, 2023-2028
  5.2.3 By Application - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Tumor Immunity Therapy Market Size, 2021 & 2028
6.2 By Region - Global Tumor Immunity Therapy Revenue & Forecasts
  6.2.1 By Region - Global Tumor Immunity Therapy Revenue, 2017-2022
  6.2.2 By Region - Global Tumor Immunity Therapy Revenue, 2023-2028
  6.2.3 By Region - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Tumor Immunity Therapy Revenue, 2017-2028
  6.3.2 US Tumor Immunity Therapy Market Size, 2017-2028
  6.3.3 Canada Tumor Immunity Therapy Market Size, 2017-2028
  6.3.4 Mexico Tumor Immunity Therapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Tumor Immunity Therapy Revenue, 2017-2028
  6.4.2 Germany Tumor Immunity Therapy Market Size, 2017-2028
  6.4.3 France Tumor Immunity Therapy Market Size, 2017-2028
  6.4.4 U.K. Tumor Immunity Therapy Market Size, 2017-2028
  6.4.5 Italy Tumor Immunity Therapy Market Size, 2017-2028
  6.4.6 Russia Tumor Immunity Therapy Market Size, 2017-2028
  6.4.7 Nordic Countries Tumor Immunity Therapy Market Size, 2017-2028
  6.4.8 Benelux Tumor Immunity Therapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Tumor Immunity Therapy Revenue, 2017-2028
  6.5.2 China Tumor Immunity Therapy Market Size, 2017-2028
  6.5.3 Japan Tumor Immunity Therapy Market Size, 2017-2028
  6.5.4 South Korea Tumor Immunity Therapy Market Size, 2017-2028
  6.5.5 Southeast Asia Tumor Immunity Therapy Market Size, 2017-2028
  6.5.6 India Tumor Immunity Therapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Tumor Immunity Therapy Revenue, 2017-2028
  6.6.2 Brazil Tumor Immunity Therapy Market Size, 2017-2028
  6.6.3 Argentina Tumor Immunity Therapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Tumor Immunity Therapy Revenue, 2017-2028
  6.7.2 Turkey Tumor Immunity Therapy Market Size, 2017-2028
  6.7.3 Israel Tumor Immunity Therapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Tumor Immunity Therapy Market Size, 2017-2028
  6.7.5 UAE Tumor Immunity Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bristol-Myers Squibb
  7.1.1 Bristol-Myers Squibb Corporate Summary
  7.1.2 Bristol-Myers Squibb Business Overview
  7.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Major Product Offerings
  7.1.4 Bristol-Myers Squibb Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.1.5 Bristol-Myers Squibb Key News
7.2 Merck & Co., Inc.
  7.2.1 Merck & Co., Inc. Corporate Summary
  7.2.2 Merck & Co., Inc. Business Overview
  7.2.3 Merck & Co., Inc. Tumor Immunity Therapy Major Product Offerings
  7.2.4 Merck & Co., Inc. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.2.5 Merck & Co., Inc. Key News
7.3 Roche AG
  7.3.1 Roche AG Corporate Summary
  7.3.2 Roche AG Business Overview
  7.3.3 Roche AG Tumor Immunity Therapy Major Product Offerings
  7.3.4 Roche AG Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.3.5 Roche AG Key News
7.4 AstraZeneca, Plc
  7.4.1 AstraZeneca, Plc Corporate Summary
  7.4.2 AstraZeneca, Plc Business Overview
  7.4.3 AstraZeneca, Plc Tumor Immunity Therapy Major Product Offerings
  7.4.4 AstraZeneca, Plc Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.4.5 AstraZeneca, Plc Key News
7.5 Sanofi S.A.
  7.5.1 Sanofi S.A. Corporate Summary
  7.5.2 Sanofi S.A. Business Overview
  7.5.3 Sanofi S.A. Tumor Immunity Therapy Major Product Offerings
  7.5.4 Sanofi S.A. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.5.5 Sanofi S.A. Key News
7.6 Dendreon Pharmaceuticals
  7.6.1 Dendreon Pharmaceuticals Corporate Summary
  7.6.2 Dendreon Pharmaceuticals Business Overview
  7.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Major Product Offerings
  7.6.4 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.6.5 Dendreon Pharmaceuticals Key News
7.7 Novartis
  7.7.1 Novartis Corporate Summary
  7.7.2 Novartis Business Overview
  7.7.3 Novartis Tumor Immunity Therapy Major Product Offerings
  7.7.4 Novartis Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.7.5 Novartis Key News
7.8 Gilead Sciences Inc.
  7.8.1 Gilead Sciences Inc. Corporate Summary
  7.8.2 Gilead Sciences Inc. Business Overview
  7.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Major Product Offerings
  7.8.4 Gilead Sciences Inc. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.8.5 Gilead Sciences Inc. Key News
7.9 IMVAQ Therapeutics
  7.9.1 IMVAQ Therapeutics Corporate Summary
  7.9.2 IMVAQ Therapeutics Business Overview
  7.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Major Product Offerings
  7.9.4 IMVAQ Therapeutics Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.9.5 IMVAQ Therapeutics Key News
7.10 Arch Oncology
  7.10.1 Arch Oncology Corporate Summary
  7.10.2 Arch Oncology Business Overview
  7.10.3 Arch Oncology Tumor Immunity Therapy Major Product Offerings
  7.10.4 Arch Oncology Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.10.5 Arch Oncology Key News
7.11 Juno Therapeutics
  7.11.1 Juno Therapeutics Corporate Summary
  7.11.2 Juno Therapeutics Business Overview
  7.11.3 Juno Therapeutics Tumor Immunity Therapy Major Product Offerings
  7.11.4 Juno Therapeutics Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.11.5 Juno Therapeutics Key News
7.12 Refuge
  7.12.1 Refuge Corporate Summary
  7.12.2 Refuge Business Overview
  7.12.3 Refuge Tumor Immunity Therapy Major Product Offerings
  7.12.4 Refuge Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.12.5 Refuge Key News
7.13 Lepu Biopharma
  7.13.1 Lepu Biopharma Corporate Summary
  7.13.2 Lepu Biopharma Business Overview
  7.13.3 Lepu Biopharma Tumor Immunity Therapy Major Product Offerings
  7.13.4 Lepu Biopharma Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.13.5 Lepu Biopharma Key News
7.14 Genoimmune
  7.14.1 Genoimmune Corporate Summary
  7.14.2 Genoimmune Business Overview
  7.14.3 Genoimmune Tumor Immunity Therapy Major Product Offerings
  7.14.4 Genoimmune Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.14.5 Genoimmune Key News
7.15 TCR Cure
  7.15.1 TCR Cure Corporate Summary
  7.15.2 TCR Cure Business Overview
  7.15.3 TCR Cure Tumor Immunity Therapy Major Product Offerings
  7.15.4 TCR Cure Tumor Immunity Therapy Revenue in Global Market (2017-2022)
  7.15.5 TCR Cure Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Tumor Immunity Therapy Market Opportunities & Trends in Global Market
Table 2. Tumor Immunity Therapy Market Drivers in Global Market
Table 3. Tumor Immunity Therapy Market Restraints in Global Market
Table 4. Key Players of Tumor Immunity Therapy in Global Market
Table 5. Top Tumor Immunity Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Tumor Immunity Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Tumor Immunity Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Tumor Immunity Therapy Product Type
Table 9. List of Global Tier 1 Tumor Immunity Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Tumor Immunity Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Tumor Immunity Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Tumor Immunity Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Tumor Immunity Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Tumor Immunity Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Tumor Immunity Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Tumor Immunity Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Tumor Immunity Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Tumor Immunity Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Tumor Immunity Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Tumor Immunity Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Bristol-Myers Squibb Corporate Summary
Table 31. Bristol-Myers Squibb Tumor Immunity Therapy Product Offerings
Table 32. Bristol-Myers Squibb Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Merck & Co., Inc. Corporate Summary
Table 34. Merck & Co., Inc. Tumor Immunity Therapy Product Offerings
Table 35. Merck & Co., Inc. Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Roche AG Corporate Summary
Table 37. Roche AG Tumor Immunity Therapy Product Offerings
Table 38. Roche AG Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 39. AstraZeneca, Plc Corporate Summary
Table 40. AstraZeneca, Plc Tumor Immunity Therapy Product Offerings
Table 41. AstraZeneca, Plc Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Sanofi S.A. Corporate Summary
Table 43. Sanofi S.A. Tumor Immunity Therapy Product Offerings
Table 44. Sanofi S.A. Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Dendreon Pharmaceuticals Corporate Summary
Table 46. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offerings
Table 47. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Corporate Summary
Table 49. Novartis Tumor Immunity Therapy Product Offerings
Table 50. Novartis Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Gilead Sciences Inc. Corporate Summary
Table 52. Gilead Sciences Inc. Tumor Immunity Therapy Product Offerings
Table 53. Gilead Sciences Inc. Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 54. IMVAQ Therapeutics Corporate Summary
Table 55. IMVAQ Therapeutics Tumor Immunity Therapy Product Offerings
Table 56. IMVAQ Therapeutics Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 57. Arch Oncology Corporate Summary
Table 58. Arch Oncology Tumor Immunity Therapy Product Offerings
Table 59. Arch Oncology Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 60. Juno Therapeutics Corporate Summary
Table 61. Juno Therapeutics Tumor Immunity Therapy Product Offerings
Table 62. Juno Therapeutics Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 63. Refuge Corporate Summary
Table 64. Refuge Tumor Immunity Therapy Product Offerings
Table 65. Refuge Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 66. Lepu Biopharma Corporate Summary
Table 67. Lepu Biopharma Tumor Immunity Therapy Product Offerings
Table 68. Lepu Biopharma Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 69. Genoimmune Corporate Summary
Table 70. Genoimmune Tumor Immunity Therapy Product Offerings
Table 71. Genoimmune Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)
Table 72. TCR Cure Corporate Summary
Table 73. TCR Cure Tumor Immunity Therapy Product Offerings
Table 74. TCR Cure Tumor Immunity Therapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Tumor Immunity Therapy Segment by Type in 2021
Figure 2. Tumor Immunity Therapy Segment by Application in 2021
Figure 3. Global Tumor Immunity Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Tumor Immunity Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Tumor Immunity Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Tumor Immunity Therapy Revenue in 2021
Figure 8. By Type - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 12. US Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 24. China Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Tumor Immunity Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Tumor Immunity Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Bristol-Myers Squibb Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Merck & Co., Inc. Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche AG Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. AstraZeneca, Plc Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Sanofi S.A. Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Gilead Sciences Inc. Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. IMVAQ Therapeutics Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Arch Oncology Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Juno Therapeutics Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Refuge Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Lepu Biopharma Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Genoimmune Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. TCR Cure Tumor Immunity Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)